Bone Biologics Corp

For the period ended Mar 31, 2025. Filed May 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 12, 2025

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Statements of Cash Flows

Condensed Consolidated Statements of Cash Flows

Three Months Ended March 31, 2025 · Three Months Ended March 31, 2024
(unaudited) · (unaudited)
Cash flows from operating activities
Net loss		$(1,017,092)		$(865,970)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		50,605		52,681
Change in fair value of warrant liability		(1,355)		(37,311)
Changes in operating assets and liabilities:
Advances on research and development contract services		49,087		-
Prepaid expenses and other current assets		71,646		99,254
Accounts payable and accrued expenses		(79,016)		(137,076)
Accrued legal settlement		-		(414,989)
Net cash used in operating activities		(926,125)		(1,303,411)
Cash flows from financing activities
Proceeds from issuance of common shares under ATM offering, net of costs		347,549		1,504,476
Net cash provided by financing activities		347,549		1,504,476
Net increase (decrease) in cash		(578,576)		201,065
Cash, beginning of period		3,325,131		3,026,569
Cash, end of period		$2,746,555		$3,227,634
Supplemental information
Income taxes paid	$	-	$	-
Noncash investing and financing activities
Options issued to settle accrued bonus		$46,183		77,400

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.